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ABSTRACT
We used DNA content flow cytometry followed by oligonucleotide array based 
comparative genomic hybridization to survey the genomes of 326 tumors, including 
41 untreated surgically resected triple negative breast cancers (TNBC). A high level 
(log2ratio ≥1) 9p24 amplicon was found in TNBC (12/41), glioblastomas (2/44), 
and colon carcinomas (2/68). The shortest region of overlap for the amplicon 
targets 9p24.1 and includes the loci for PD-L1, PD-L2, and JAK2 (PDJ amplicon). In 
contrast this amplicon was absent in ER+ (0/8) and HER2+ (0/15) breast tumors, 
and in pancreatic ductal adenocarcinomas (0/150). The PDJ amplicon in TNBCs was 
correlated with clinical outcomes in group comparisons by two-sample t-tests for 
continuous variables and chi-squared tests for categorical variables. TNBC patients 
with the PDJ amplicon had a worse outcome with worse disease-free and overall 
survival. Quantitative RT-PCR confirmed that the PDJ amplicon in TNBC is associated 
with elevated expression of JAK2 and of the PD-1 ligands. These initial findings 
demonstrate that the PDJ amplicon is enriched in TNBC, targets signaling pathways 
that activate the PD-1 mediated immune checkpoint, and identifies patients with a 
poor prognosis.
INTRODUCTION
There is an emerging recognition of the role 
of immune checkpoints in the pathogenesis of solid 
tumors [1]. Distinct inhibitory pathways serve to regulate 
T cell activation and function. These include the immune 
regulatory molecules PD-L1 and PD-L2 that limit the 
duration and the level of the T-cell response. Increased 
expression of these ligands of the immune checkpoint 
receptor PD-1 has been reported in human tumors 
[2–4]. PD-1 is a CD28 and CTLA-4 homologue that is 
normally induced on activated T cells, but the chronic 
antigenic exposure in cancer may lead to high levels of 
PD-1 and T cell exhaustion [5]. Consequently PD-1 and 
its ligands are being investigated as candidate biomarkers 
for response to targeted immune checkpoint blockade 
in clinical trials of an increasing variety of tumors. Two 
PD-1 inhibitors, nivolumab and pembrolizumab, have 
been approved for clinical use in melanoma and are in 
clinical trials in other solid tumors [6]. In melanoma, the 
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combination of nivolumab plus ipilimumab which targets 
the PD-1 homologue CTLA-4 was associated with a 
> 80% decline in tumor burden at 12 weeks in respondents 
and a 53% overall response rate (ORR) [7]. More recent 
studies with a larger cohort of patients with untreated 
metastatic melanoma reported an ORR of 61% for the 
combination therapy with complete responses in 22% of 
patients [8]. However clinical studies have been limited by 
the lack of predictive biomarkers of disease response, the 
complexity of tumor genomes, and the degeneracy of the 
receptor/ligand interactions.
The Janus kinase 2 gene (JAK2) is one of four 
members of the JAK family (which includes JAK1, 
JAK2, JAK3 and non-receptor protein-tyrosine kinase 2 
(TYK2) [9]. JAKs associate with the cytoplasmic 
portion of a variety of transmembrane cytokine 
and growth factor receptors important for signal 
transduction in hematopoietic cells. Receptor binding 
by extracellular ligand causes receptor multimerization 
and brings JAK proteins together to allow activation by 
transphosphorylation. Activated JAK2 has emerged as 
an important target in myeloproliferative disorders, and 
increasingly, in solid tumors [10]. Significantly JAK2 has 
been implicated in interleukin (IL)-6-dependent breast 
cancer stem cell self-renewal [11], and in both IL-6- and 
IL-8-dependent growth of triple-negative breast cancers 
(TNBCs) [12]. Pre-clinical studies have implicated 
JAK2 signaling as a mechanism of escape from targeted 
therapies in TNBC and as a promoter for the emergence 
of more invasive tumor cells [13]. Thus, JAK2 inhibitors 
are being evaluated in patients with breast and other 
solid tumors. However a case control study of 223 breast 
tumors reported an association between increased JAK2 
mRNA levels and favorable prognosis [14], and a strong 
correlation between JAK2 mRNA levels with the presence 
of tumor-infiltrating lymphocytes (TILs). The protective 
effect of elevated JAK2 expression was not associated 
with increased JAK2 protein levels in the tumor epithelial 
cells. These observations suggest that therapeutic targeting 
of JAK2 expression may abrogate the potential benefits 
arising from an antitumor immune response. Thus the 
clinical significance of selective amplification and 
overexpression of JAK2 arising from the often highly 
aberrant genomic landscapes of solid tumors remains to 
be elucidated.
The PD-L1 and PD-L2 genes localize to 9p24.1 
adjacent to JAK2 and there is emerging data that 
an amplicon targeting this 9p24.1 locus is present 
in lymphomas and a subset of EBV-positive gastric 
cancers [15, 16]. Furthermore JAK2 has been shown 
to up-regulate the transcription of both PD-1 ligands 
and increase sensitivity to JAK2 inhibitors in a dose 
dependent manner [16]. We hypothesized that targeted 
amplification of 9p24.1 in tumor genomes would result 
in co-amplification of PD-L1, PD-L2, and JAK2, identify 
a distinct molecular subtype arising in multiple cancers, 
and provide a candidate biomarker for patients who may 
benefit from immune checkpoint targeted therapies. In 
order to address tissue and clonal heterogeneity in clinical 
samples we used DNA content based flow sorting to 
identify and purify distinct tumor populations in each 
tissue of interest [17–19]. There are well-established DNA 
staining based methods for isolating nuclei of aneuploid, 
tetraploid, and diploid neoplastic populations from solid 
tumor samples [20–23]. Individual populations of cells 
or nuclei can be objectively and quantitatively purified 
to greater than 95% purity for molecular analyses even 
in heavily admixed and sub-optimal clinical samples. 
We have developed and extensively validated flow 
cytometry based methodologies to study a wide variety 
of clinical samples including small needle biopsies, post 
treatment tissues, and formalin fixed paraffin embedded 
(FFPE) tissues with high definition genome assays such 
as oligonucleotide based array comparative genomic 
hybridization (aCGH) and next generation sequencing 
NGS [18, 24].
To test our hypothesis we surveyed the genomes 
of 326 clinical samples representing pancreatic ductal 
adenocarcinomas (PDA) (n = 150), glioblastomas (n = 44), 
colorectal carcinomas (n = 68), and breast carcinomas 
(n = 64). Each tumor sample in this study was flow 
sorted prior to copy number analysis with oligonucleotide 
based aCGH. These data were then used to determine 
the prevalence of amplification of PD-L1, PD-L2, and 
JAK2 at chromosome 9p24.1 within each tumor type. The 
presence of this “PDJ” amplicon was then correlated with 
expression of JAK2 and the PD-1 ligands, and to clinical 
outcomes in a subset of patients.
RESULTS
We detected and sorted an aneuploid and/or a 
proliferating tumor fraction from each clinical sample 
in this study. These fractions were gated during sorting 
providing highly purified and objectively defined tumor 
populations from each sample for analysis. The tissues 
included triple negative breast cancer n = 41, HER2+ 
breast cancer n = 15, ER+HER2- breast cancer n = 8, 
pancreatic adenocarcinoma n = 150 (including 30 liver 
metastases), colorectal carcinoma n = 68, and glioblastoma 
n = 44. These included both fresh frozen and formalin 
fixed paraffin embedded (FFPE) clinical samples. The 
tumor cellularity prior to sorting varied extensively from 
less than 10% to greater than 70% across tissue types. 
The genomes of each sorted tumor cell population were 
interrogated with whole genome oligonucleotide based 
aCGH. Copy number aberrant intervals were identified 
and their genomic boundaries mapped using a step gram 
algorithm [25]. Amplicons were then ranked within 
each sample based on their fold change and their overall 
prevalence in tumor genomes. A recurring top ranked and 
high level (log2ratio ≥1) amplicon that targeted 9p24.1 
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was detected in 12/41 TNBCs, 2/68 colon carcinomas, 
and 2/44 glioblastomas (Figs. 1 and 2). In contrast this 
amplicon was absent in ER+ (n = 8) and HER2+ (n = 15) 
breast tumors, and in pancreatic ductal adenocarcinomas 
(n = 150). The shortest region of overlap (SRO) spanned 
777 kb and included the PD-1 ligands PD-L1, PD-L2, and 
the Janus kinase 2 (JAK2) loci (Fig. S1). The height of this 
recurring amplicon included mean log2ratios >4 consistent 
with amplification of genomic drivers such as HER2 and 
MYC described in breast cancer and other solid tumor 
genomes.
In order to determine the effect of the PDJ amplicon 
on JAK2, PD-L1, and PD-L2 expression we selected 31 
TNBC samples, 16 of which were profiled in our copy 
number analysis, for qRT-PCR analysis. We used a pooled 
sample comprised of an unrelated normal breast, and 
individual TNBC, ER+, and HER2+ tumor tissues to 
generate a standard curve for assaying JAK2, PD-L1 and 
PD-L2 expression in our TNBC cohort. Tumors with a 
high level amplicon (4/16 TNBCs surveyed by qRT-PCR) 
had significantly higher expression of JAK2 and PD-L1 
genes compared to those without the amplicon (Fig. 2). 
The latter included samples with low level copy number 
gains (log2ratio >0 and <1) at 9p24.1 including increases of 
whole 9p arm and polysomy of chromosome 9. In addition 
we identified another TNBC in the subset of 15 tumors 
without aCGH data with concurrent elevated expression 
of JAK2 and PD-L1 (Fig. S2). PD-L2 expression was also 
elevated in the presence of the PDJ amplicon however it 
did not reach statistical significance ( p < 0.0645) in this 
preliminary study. These observations are consistent with 
studies showing that genomic amplification of 9p24.1 
leads to coordinated overexpression of these genes in 
human tumors [15, 16].
Clinical data was available on 36 of 41 (88%) of 
the TNBC patients that were flow sorted then profiled 
for copy number (Table 1). Patients with the high level 
PDJ amplicon (n = 8) were noted to have larger tumors 
(mean 3.9 cm vs. 1.9 cm, p = 0.04) and a higher incidence 
of lymph node metastases (75% vs. 26%, p = 0.01). 
Lymphocytic infiltration was noted in 4 of the 36 patients, 
none of whom had the PDJ amplicon in their tumor 
Figure 1: Whole genome and chromosome 9 aCGH plots of flow sorted tumor populations. A. Colorectal (CRC) and 
B–C. triple negative breast cancers (TNBC) with high level 9p24.1 amplicon. Amplicons were scored according to log2ratios >1. Blue 
arrows denote JAK2 locus.
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genome. Twenty nine of these 36 TNBC patients received 
chemotherapy after definitive surgical therapy. The 
disease-free survival rate at 5 years was 25% in the PDJ 
amplified patients, and 66% in the unamplified patients 
( p = 0.005) (Fig. 3). Overall survival (OS) at 5 years 
was 25% in the PDJ amplified patients, compared with 
69% in the unamplified patients ( p = 0.004). Thus our 
preliminary results suggest that the presence of the PDJ 
amplicon defines a clinically significant subset of high-
risk TNBC patients.
DISCUSSION
Studies in gastric cancer and in lymphomas have 
described a recurring 9p24.1 amplicon that includes 
PD-L1, PD-L2,  and JAK2 [15, 16]. The presence of the 
amplicon was associated in a subset of each tumor type 
with distinct pathological and clinical features. Functional 
studies revealed that JAK2 is a transcriptional activator 
of both PD-1 ligands [16] and that sensitivity to JAK2 
inhibition occurs in a dose-dependent manner [26]. 
Thus genomic amplification of 9p24.1 may provide a 
selective tumor cell dependent increase in both JAK2 and 
immune checkpoint signaling. In addition, copy number 
gains on chromosome 9 that include 9p24.1 and elevated 
expression of PD-L1 within tumor cells have recently been 
associated with substantial therapeutic activity in patients 
with advanced or refractory Hodgkin’s lymphoma treated 
with the PD-1 inhibitor nivolumab [27]. Notably, two early 
phase I trials of PD-1/PD-L1 blockade (pembrolizumab 
or MPDL3280A) in TNBC have demonstrated overall 
response rates of 15–20% [28, 29].
PD-L1 expression across multiple solid tumors 
varies significantly by tumor type and appears common 
in both tumor-infiltrating immune cells and in tumor 
cells [4, 30]. Elevated PD-L1 expression from tumor 
infiltrating immune cells had a stronger association with 
clinical response than that observed with expression from 
the tumor cells [4]. Significantly elevated expression of 
JAK2 in the non-epithelial compartment of breast tumors 
Figure 2: The 9p24 amplicon in a triple negative breast cancer genome. A. Flow histogram of sorted 3.2N TNBC  
population from FFPE tissue. B. Chromosome 9 CGH plot and detection of 9p24 amplicon. C. Gene specific view of amplicon.  
Red shaded area denotes ADM2 defined copy number aberrant region. D. Gene expression of JAK2, PD-L1, and PD-L2 in TNBC. 
Comparisons and correlations between the expression levels of PD-L1, PD-L2, and JAK2 genes and copy number status of chromosome  
9p24.1 were performed using an unpaired t test and variation among and between groups were calculated using an ANOVA test 
(GraphPad Prism 6).
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Table 1: Comparison between patients with and without PDJ amplification
Not Amplified (N = 28) Amplified (N = 8) Total (N = 36) p value
Age [years] 0.791
 Mean (SD) 53.4 (12.88) 54.8 (8.71) 53.7 (11.98)
 Median 54.0 53.5 54.0
 Range (29.0–78.0) (45.0–72.0) (29.0–78.0)
Tumor Size [cm] 0.041
 Mean (SD) 1.9 (0.86) 3.9 (3.88) 2.4 (2.11)
 Median 1.9 2.5 2.0
 Range (0.5–4.0) (0.4–11.0) (0.4–11.0)
Grade 0.632
 1 1 (3.6%) 0 (0%) 1 (2.8%)
 2 7 (25%) 1 (12.5%) 8 (22.2%)
 3 20 (71.4%) 7 (87.5%) 27 (75%)
Lymphocytic 
Infiltrates
0.212
 Missing 10 (.%) 2 (.%) 12
 No 14 (77.8%) 6 (100%) 20 (83.3%)
 Yes 4 (22.2%) 0 (0%) 4 (16.7%)
Lymph Nodes 0.012
 Missing 1 (%) 0 (.%) 1
 Negative 20 (74.1%) 2 (25%) 22 (62.9%)
 Positive 7 (25.9%) 6 (75%) 13 (37.1%)
Cancer Stage 0.042
 Missing 1 (.%) 0 (.%) 1
 Stage I 11 (40.7%) 1 (12.5%) 12 (34.3%)
 Stage II 13 (48.1%) 3 (37.5%) 16 (45.7%)
 Stage III 3 (11.1%) 4 (50%) 7 (20%)
Surgical 
Treatment 0.70
2
 Missing 9 (.%) 2 (.%) 11
  Breast 
Conservation 
Therapy (BCT)
8 (42.1%) 2 (33.3%) 10 (40%)
 Mastectomy 11 (57.9%) 4 (66.7%) 15 (60%)
Chemotherapy 0.102
 Neoadjuvant 1 (3.6%) 2 (25%) 3 (8.3%)
 No 4 (14.3%) 0 (0%) 4 (11.1%)
 Yes 23 (82.1%) 6 (75%) 29 (80.6%)
(Continued)
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has been associated with a better prognosis and decreased 
risk of recurrence [14]. Thus an important clinical question 
is the role of a tumor cell driven elevation in JAK2 and 
PD-1 ligands versus increases arising from immune cells 
in solid tissue cancers [6, 27].
Previous in vitro studies of a 9p amplicon in a small 
panel of established breast cancer cell lines excluded 
JAK2, PD-L1, and PD-L2 loci from the SRO reported 
[31]. However JAK2 copy number levels assessed in 
bulk TNBC biopsies by targeted resequencing of a 
panel of 196 cancer associated genes have been reported 
to be elevated in residual disease post neoadjuvant 
chemotherapy. The JAK2 amplification was associated 
with poor regression free survival (RFS) and predicted 
poor OS in a subset (~10%) of TNBCs [32]. The 
prevalence of JAK2 amplification was noted to be higher 
in these post treatment TNBCs than reported for treatment 
naïve TNBCs in TCGA. The latter are based on single 
nucleotide polymorphism (SNP) array data of bulk tumor 
samples. Consequently it remained to be resolved whether 
JAK2 amplifications and the potential co-amplifications 
of PD-L1 and PD-L2 are present in untreated TNBCs, and 
whether genomic amplification at 9p24.1 may provide 
a biomarker for clinical outcome. Furthermore recent 
correlative studies with FISH based markers in lymphoma 
have proposed that even tumors with low level 9p gains 
and chromosome 9 polysomy may benefit from PD-1 
targeted therapies [27].
Our preliminary results with highly purified flow 
sorted clinical samples and an array platform designed 
for whole genome copy number measures suggest that 
the PDJ amplicon has a SRO that targets JAK2 and the 
PD-1 ligands, is enriched in a subset of TNBCs with poor 
outcomes prior to therapy, and is distinct from background 
genomic aberrations affecting chromosome 9. Given the 
coordinated overexpression of PD-L1, PD-L2, and JAK2, 
antagonists targeting PD-1 signaling and JAK2 inhibitors 
should be evaluated in the context of PDJ amplification. 
Thus we propose that the PDJ amplicon provides a 
candidate biomarker for identifying high-risk patients and 
for advancing emerging immunotherapies in TNBC. The 
absence of this amplicon in pancreatic adenocarcinoma 
samples and its relatively low frequencies in colorectal 
cancers and glioblastomas are consistent with relatively 
low response rates reported in these and other solid tumors 
when compared to TNBC [33, 34]. However the presence 
and role of the PDJ amplicon in a smaller subset (2–5%) 
of colorectal cancers, including primary and matching 
Not Amplified (N = 28) Amplified (N = 8) Total (N = 36) p value
Radiation 
[Mastectomy only] 0.88
2
 Missing 17 (.%) 4 (.%) 21
 No 5 (45.5%) 2 (50%) 7 (46.7%)
 Yes 6 (54.5%) 2 (50%) 8 (53.3%)
1Two-Sample T-Test
2Chi-Square
Figure 3: Clinical outcomes for TNBC patients with or without PDJ amplicon. A. Progression free survival. Lower disease-
free survival at 5 years 25.0% vs. 66.0%, p = 0.005. B. Overall survival. Lower overall survival at 5 years 25.0% vs. 69.0%, p = 0.004. 
Median follow up is 4.7 years (range 0.9–12.0 years).
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lymph node biopsies (Fig. S3), and glioblastomas warrants 
further investigation.
Given the highly aberrant genomic landscapes of 
TNBCs and other solid tumors, alterations that disrupt 
immune regulatory signaling pathways upstream or 
downstream of PDJ amplicon may provide additional 
biomarkers for this emerging class of therapies [35]. 
Studies in cell line models suggest that deletions in PTEN 
and disruption of AKT signaling can increase PD-L1 
levels [36]. Our use of flow sorted clinical samples 
provides a robust objective method to detect somatic 
lesions targeting clinically actionable pathways [18, 24]. 
For example we detected focal deletions of PTEN in 
the tumor genomes of 5/12 PDJ positive TNBCs (Fig. 4 
and Fig. S4). Future studies will incorporate flow sorted 
tissue samples and both copy number and next generation 
sequencing analyses to provide a more comprehensive and 
unbiased profile of the genomic landscapes of tumors with 
the PDJ amplicon. Of significant interest will be biopsies 
from patients enrolled in clinical trials with agents that 
target the PD-1 immune checkpoint. The ability to 
discriminate mutations and genomic lesions including 
the PDJ amplicon arising in the epithelial component of 
solid tumors and to comprehensively interrogate genomes 
in the pre and post adjuvant setting, regardless of tumor 
cell content, will be essential to understand clinical 
responses and to advance effective immunotherapies. 
These data will also be used to develop robust clinically 
relevant assays (e.g. targeted resequencing, FISH, IHC) to 
efficiently identify those patients with the PDJ amplicon. 
We propose that the PDJ amplicon in TNBC and other 
solid tumors represents a novel candidate biomarker with 
broad application for cancer research and for advancing 
personalized therapies for cancer patients.
MATERIALS AND METHODS
Clinical samples
TNBC, ER+, and HER2+ samples were obtained 
under approval from the Mayo Clinic Institutional Review 
Board prior to undertaking this study (IRB protocol 
08-006579). Tumor specimens were obtained from 
formalin fixed paraffin embedded (FFPE) archived breast 
cancer samples obtained at the time of definitive surgical 
resection. All breast cancers underwent central pathologic 
review, and were evaluated by IHC for estrogen receptor 
(ER), progesterone receptor (PR), and by IHC +/− FISH 
for Her2/neu under CLIA/CAP guidelines. TNBC samples 
were also obtained from The Inflammatory Breast Cancer 
Research Foundation (IBCRF) Biobank. Samples were 
collected following informed consent by the IBCRF under 
approval of their IRB and their Medical Advisory Board. 
Additional flow sorted TNBC data was from a previous 
study of breast cancer genomes that was performed with 
informed consent and ethics committee approvals [37]. 
Figure 4: PTEN homozygous deletion in PDJ+ triple negative breast cancer genome. A. Flow histogram of sorted 5.0N 
TNBC population from FFPE tissue. B–C. Chromosome 10 and chromosome 9 CGH plots. D. Gene specific view of PTEN homozygous 
deletion. Blue shaded area denotes ADM2 defined copy number aberrant region.
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PDA samples were from previous studies obtained 
under a WIRB protocol (20040832) for an NIH funded 
biospecimen repository (NCI P01 Grant CA109552), 
Stand up To Cancer clinical trials 2026001 and 2026003, 
and with approved consent of the Ethics Committee of 
Basel (252/08, 302/09).The glioblastoma samples were 
collected for another previous study with informed consent 
from patients at the Neurosurgery Department of the 
Centre Hospitalier in Luxembourg (CHL) [38]. Samples 
were approved for study by the National Ethics Committee 
for Research (CNER) of Luxembourg. In all cases written 
consent was obtained. De-identified colon samples did 
not qualify as human subjects according to guidelines 
administered by the Translational Genomics Research 
Institute (TGen) Office of Research Compliance and were 
collected under an institutional blanket exemption as part 
of different research initiatives and from the Cooperative 
Human Tissue Network (CHTN).
FFPE sample preparation
Prior to sorting, excess paraffin was removed 
with a scalpel from either side of 40–60 um scrolls 
then processed according to our published methods 
[24]. Briefly each sectioned piece was collected into 
individual microcentrifuge tubes then washed three 
times with 1 ml Xylene for 5 minutes to remove 
remaining paraffin. Each sample was rehydrated in 
sequential ethanol washes (100% 5 minutes × 2, then 
95%, 70%, 50% and 30% ethanol) and washed 2 times 
in 1 ml 1 mM EDTA pH 8.0. A 1 ml aliquot of 1 mM 
EDTA pH 8.0 was added to the samples and incubated at 
95°C for 80 minutes to facilitate the removal of protein 
cross-links present in FFPE tissue. Samples were then 
cooled to room temperature for ≥5 minutes, followed by 
addition of 300 ul PBS pH 7.4 and gentle centrifugation 
for 2 minutes at 3.6 × g. The supernatant was carefully 
removed and the pellet washed three times with 1 ml 
PBS pH 7.4/0.5 mM CaCl2 to remove EDTA. Each 
sample was digested overnight (6–17 hours) in 1 ml 
of a freshly prepared enzymatic cocktail containing 
50 units/ml of collagenase type 3, 80 units/ml of purified 
collagenase, and 100 units/ml of hyaluronidase in PBS 
pH 7.4/0.5 mM CaCl2 buffer. Following overnight 
digestion 500 ul NST buffer (146 mM NaCl, 10 mM 
Tris-HCl, pH 7.5, 1 mM CaCl2, 0.5 mM MgSO4, 21 mM 
MgCl2, 0.05% bovine serum albumin, 0.2% Nonidet 
P40 (Sigma)) with 4, 6-diamindino-2-phenylindole 
(DAPI; 10 μg/ml) was added to each sample to facilitate 
pelleting. Samples were centrifuged for 5 minutes at 
3000 × g, after which pellets were resuspended in 750 ul 
of NST/10% fetal bovine serum and then passed through 
a 25 G needle 10–20 times. We used a single 50 μm 
scroll from each FFPE tissue block to obtain sufficient 
numbers of intact nuclei for subsequent sorting and 
molecular assays.
Flow cytometry
Biopsies were minced in the presence of NST buffer 
and DAPI according to published protocols [23, 39, 40]. 
Prior to sorting each sample was filtered through a 35 um 
mesh and collected into a 5 ml Polypropylene round 
bottom tube. The mesh was rinsed with an additional 
750 ul of NST/10% fetal bovine serum and placed on ice 
while processing remaining samples. The total volume in 
the tube for each sample was approximately 1.5 ml. An 
equal volume of 20 ug/ml DAPI was added to each tube 
to achieve a final concentration of 10 ug/ml DAPI for 
flow sorting with a BD Influx cytometer with ultraviolet 
excitation (Becton-Dickinson, San Jose, CA). The optimal 
settings for sorting FFPE samples with the Influx sorter 
were as follows: Drop formation was achieved with piezzo 
amplitude of 6–10 volts and a drop frequency of 30 khertz. 
The sort mode was set to purity yield with a drop delay 
of 31.5–32. Sheath fluid pressure was typically 17–18 psi 
with a 100 um nozzle. For single parameter DNA content 
assays DAPI emission was collected at >450 nm. DNA 
content and cell cycle were then analyzed using the 
software program MultiCycle (Phoenix Flow Systems, 
San Diego, CA).
DNA extraction
DNA from sorted nuclei was extracted using an 
amended protocol from QIAamp® DNA Micro Kit from 
Qiagen (Valencia, CA). Briefly each sorted sample was 
resuspended in 180 ul buffer ATL and 20 ul proteinase 
K (20 mg/ml) then incubated for 3 hours at 56°C for 
complete lysis. Samples were bound and washed according 
to QIAamp® DNA Micro Kit instructions, eluted into 50 ul 
of H20, then precipitated overnight with 5 ul 3 M sodium 
acetate and 180 ul 100% EtOH. Each sample was then 
centrifuged for 30 minutes at 20, 000 × g, washed in 1 ml 
of 70% EtOH for 30 minutes at 20, 000 × g. The samples 
were carefully decanted and the DNA pellet was dried 
by speed vacuum then resuspended in a small volume 
(e.g. 10–50 ul) of H20 for final concentrations suitable for 
accurate quantitation.
aCGH analysis
DNAs were treated with DNAse 1 prior to Klenow-
based labeling. High molecular weight reference templates 
were digested for 30 minutes while the smaller fragmented 
FFPE-derived DNA samples were digested for only 
1 minute. In each case 1 ul of 10× DNase 1 reaction buffer 
and 2 ul of DNase 1 dilution buffer were added to 7 ul 
of DNA sample and incubated at room temperature then 
transferred to 70°C for 30 minutes to deactivate DNase 1. 
Sample and reference templates were then labeled with 
Cy-5 dUTP and Cy-3 dUTP respectively using a BioPrime 
labeling kit (Invitrogen, Carlsbad, CA) according to our 
published protocols [18]. All labeling reactions were 
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assessed using a Nanodrop assay (Nanodrop, Wilmington, 
DE) prior to mixing and hybridization to CGH arrays 
(Agilent Technologies, Santa Clara, CA) for 40 hours in 
a rotating 65°C oven. All microarray slides were scanned 
using an Agilent 2565C DNA scanner and the images were 
analyzed with Agilent Feature Extraction version 10.7 
using default settings. The aCGH data was assessed with 
a series of QC metrics then analyzed using an aberration 
detection algorithm (ADM2) [25]. The latter identifies 
all aberrant intervals in a given sample with consistently 
high or low log ratios based on the statistical score derived 
from the average normalized log ratios of all probes in 
the genomic interval multiplied by the square root of 
the number of these probes. This score represents the 
deviation of the average of the normalized log ratios from 
its expected value of zero and is proportional to the height 
h (absolute average log ratio) of the genomic interval, and 
to the square root of the number of probes in the interval. 
All aCGH data in this paper have been deposited at the 
National Center for Biotechnology Information Gene 
Expression Omnibus (accession number in progress).
Expression analysis
Total RNA was extracted from one whole-tissue 
50 μm thick section using RNeasy FFPE RNA Isolation 
Kit (Qiagen). RNA quantification was performed using 
Qubit 2.0 fluorometer (Life Technologies) and Qubit RNA 
HS assay kit (molecular probes). Reverse transcription was 
carried out using SuperScript® VILO™ cDNA Synthesis 
Kit (Life Technologies) and 200 ng of RNA per reaction, 
with triplicate reactions performed for each sample [41]. 
Each of the 31 samples produced sufficient RNA yield 
and quality. Quantitative Real-Time PCR was performed 
for CD274, PDCD1LG2, and JAK2 (Hs01125301_m1, 
Hs01057777_m1 Hs00234567_m1, respectively; Life 
Technologies) with TaqMan® chemistry on the ABI Prism 
7900HT (Applied Biosystems), using the standard curve 
method. Furthermore, two reference genes were used 
TFRC and MRPL19 (Hs00174609_m1, Hs00608519_m1, 
respectively; Life Technologies), previously selected as 
effectively normalizing for degradation of the FFPE- 
RNA. Target gene expression levels were normalized 
to the geometric mean of the two reference genes and 
normalized to a pool of RNAs prepared from a normal and 
from 3 FFPE breast tumors (TNBC, ER+, and HER2+). 
All statistical comparisons and correlations between the 
expression levels of PD-L1, PD-L2, and JAK2 genes and 
copy number status of chromosome 9p24.1 were performed 
using an unpaired t test and variation among and between 
groups were calculated using an ANOVA test (GraphPad 
Prism 6). The p-values < 0.05 were considered significant.
Statistical analysis
Group comparisons used two-sample t-tests for 
continuous variables and chi-squared tests for categorical 
variables. Disease-free survival time was defined as the 
time from primary surgery to first local, regional, or 
distant recurrence or death regardless of cause. Overall 
survival analysis included all deaths as events regardless 
of cause. Disease-free and overall survival rates at 5 years 
were estimated using the method of Kaplan and Meier. 
Disease-free survival and overall survival were compared 
between groups using a log-rank test. Median follow-up 
was 4.7 years (range 0.9–12.0 years). P-values < 0.05 
were considered statistical significant throughout.
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